| Project/Area Number |
20591505
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
MAEBAYASHI Katsuya Tokyo Women's Medical University, 医学部, 講師 (60332350)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
AKAMURA Kaori 東京女子医科大学, 医学部, 助教 (40339023)
IYOZUKA Makoto 東京女子医科大学, 医学部, 助教 (90366344)
ASHIMOTO Yaichiro 東京女子医科大学, 医学部, 助教 (20385420)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 膠芽腫 / 放射線治療 / 抗癌剤 / 分子標的薬剤 |
|---|
| Research Abstract |
In our clinical data, the prognosis of glioblastoma was significantly poor than that of Grade3 Glioma. The duration to recurrence of glioblastoma was shorter and the growth rate in glioblastoma after recurrence was greater. However, the rate of the in-field recurrence of both Glioblastoma and Grade3Glioma was at the same level in approximately 80%-85%. From these clinical results, we considered that the one of factors to improve the prognosis of glioblastoma was to inhibit the growth rate, and we conducted basic research about growth factors in vitro. In the result, we found that simultaneous combination of EGFR inhibitors and radiation exposure had radiosensitization, furthermore we discovered the phenomenon that might be mechanism of radiosensitizing with the EGFR inhibitor.
|
